Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07265947 · ClinicalTrials.gov registry record · Phase 2
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
A Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma, sponsored by Tyra Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 2
- Study locations
NCT07265947 is a Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma that is actively recruiting participants, run by Tyra Biosciences. The registered enrollment target is 230 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07265947, a Phase 2 study of Low-grade Upper Tract Urothelial Carcinoma, is actively recruiting participants, sponsored by Tyra Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
Conditions Studied
Interventions
- DRUG Dabogratinib (TYRA-300) 60mg
- DRUG Dabogratinib (TYRA-300) 80mg
- DRUG Dabogratinib (TYRA-300) TBD
Study Locations (2)
Indiana
- First Urology - Jeffersonville
Tennessee
- Urology Associates, P C - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2030-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07265947
The ClinicalTrials.gov registry entry for NCT07265947 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low-grade Upper Tract Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Dabogratinib (TYRA-300) 60mg is the first listed.
NCT07265947 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07265947 about?
NCT07265947 is a clinical study titled "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma". A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
What is the current status of trial NCT07265947?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2025-12-22. Estimated completion is 2030-11.
What conditions does trial NCT07265947 study?
This clinical trial studies the following conditions: Low-grade Upper Tract Urothelial Carcinoma.
What interventions are being tested in trial NCT07265947?
The interventions under investigation include: Dabogratinib (TYRA-300) 60mg (DRUG), Dabogratinib (TYRA-300) 80mg (DRUG), Dabogratinib (TYRA-300) TBD (DRUG).
Who is sponsoring clinical trial NCT07265947?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07265947 being conducted?
This trial has 2 study locations across Indiana, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-grade Upper Tract Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.